Skip to main content
PMC home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1988 Apr;26(2):139–144. doi: 10.1007/BF00205607

Role of proliferation in LAK cell development

Frederick J Ramsdell 1, Hungyi Shau 2, Sidney H Golub 1,2,✉
PMCID: PMC11038982  PMID: 3129192

Abstract

Lymphokine-activated killer (LAK) cell activity may be largely the result of activation and/or expansion of peripheral blood natural killer cells by culture with interleukin-2 (IL-2). We have examined the role of proliferation in LAK cell development by either inhibiting or enhancing the proliferative potential of peripheral blood lymphocytes. Inhibition of proliferation was accomplished using irradiation, mitomycin C, or the iron chelator deferoxamine. For each of these agents, a dose-dependent inhibition of proliferation was observed. At doses of inhibitor which nearly completely blocked thymidine uptake, the development of LAK activity was only partially impaired. The mitogenic lectins phytohemagglutinin (PHA) and concanavalin A (Con A) augmented the proliferative response of peripheral blood lymphocytes to IL-2. However, augmentation by PHA, but not Con A, consistently resulted in a decrease in LAK activity. This inhibition of LAK activity by PHA did not appear to be due to inhibition of the effector cell, nor to preferential expansion of irrelevant cells. These data suggests that not all LAK activity is dependent on proliferation, and that high levels of proliferation in the presence of IL-2 do not necessarily lead to LAK activity.

Keywords: Natural Killer, Natural Killer Cell, Thymidine, Mitomycin, Peripheral Blood Lymphocyte

Footnotes

This work was supported in part by U.S. Public Health Service Grant CA-34442 (S. H. G.) and pre-doctoral training grant CA-09120 (F. J. R.)

References

  • 1.Damle NK, Doyle LV, Bradley EC. Interleukin 2-activated human killer cells are derived from phenotypically heterogeneous precursors. J Immunol. 1986;137:2814. [PubMed] [Google Scholar]
  • 2.D'Amore P, Golub SH. Suppression of human NK cell cytotoxicity by an MLC-generated cell population. J Immunol. 1985;134:272. [PubMed] [Google Scholar]
  • 3.Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA. Lymphokine-activated killer cell phenomenon: Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med. 1982;155:1823. doi: 10.1084/jem.155.6.1823. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Grimm EA, Ramsey KM, Mazumder A, Wilson A, Djeu DJ, Rosenberg SA. Lymphokine-activated killer phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes and natural killer cells. J Exp Med. 1983;157:884. doi: 10.1084/jem.157.3.884. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Harel-Bellan A, Bertoglio J, Quillet A, Marchoil C, Wakasugi H, Mishall Z, Frudelizi D. Interleukin 2 (IL-2) upregulates its own receptor on a subset of human peripheral blood lymphocytes and triggers their proliferation. J Immunol. 1986;136:2463. [PubMed] [Google Scholar]
  • 6.Itoh K, Tilden AB, Kumagai K, Balch CM. Leu 11b+ lymphocytes with natural killer (NK) activity are precursors of recombinant interleukin 2 (rIL-2)-induced activated killer (AK) cells. J Immunol. 1985;134:802. [PubMed] [Google Scholar]
  • 7.Kaufmann Y, Levanon M, Davidsohn J, Ramot B. Interleukin 2 induces human acute lymphocytic leukemia cells to manifest lymphokine-activated-killer (LAK) cytotoxicity. J Immunol. 1987;139:977. [PubMed] [Google Scholar]
  • 8.London L, Perussia B, Trinchieri G. Induction of proliferation in vitro of resting human natural killer cells: IL 2 induces into cell cycle most peripheral blood NK cells, but only a minor subset of low density T cells. J Immunol. 1986;137:3845. [PubMed] [Google Scholar]
  • 9.Malkovsky M, Jira M, Madar J, Malkovska V, Loveland B, Asherson GL. Generation of lymphokine-activated killer cells does not require DNA synthesis. Immunology. 1987;60:471. [PMC free article] [PubMed] [Google Scholar]
  • 10.Merluzzi VJ, Trail PA, Last-Barney K. Differential expression of lymphokine-activated killer cells in adoptive transfer experiments utilizing fractionated bone marrow. J Immunol. 1986;137:2425. [PubMed] [Google Scholar]
  • 11.Morgan DA, Ruscetti FW, Gallo R. Selective in vitro growth of T-lymphocytes from normal human bone marrows. Science. 1976;193:1007. doi: 10.1126/science.181845. [DOI] [PubMed] [Google Scholar]
  • 12.Ochoa AC, Gromo G, Alter BJ, Sondel PM, Bach FH. Long-term growth of lymphokine-activated killer (LAK) cells: Role of anti- CD3, β-IL-1, interferon-γ and -β. J Immunol. 1987;138:2728. [PubMed] [Google Scholar]
  • 13.Phillips JH, Lanier LL. Dissection of the lymphokine-activated killer phenomenon: contribution of peripheral blood natural killers cells and T lymphocytes to cytolysis. J Exp Med. 1986;164:814. doi: 10.1084/jem.164.3.814. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Pross HF, Baines MG, Rubin P, Shragge P, Patterson MS. Spontaneous human lymphocyte-mediated cytotoxicity against tumor target cells. IX. The quantitation of natural killer cell activity. J Clin Immunol. 1981;1:51. doi: 10.1007/BF00915477. [DOI] [PubMed] [Google Scholar]
  • 15.Ramsdell FJ, Golub SH. Generation of lymphokine-activated killer cell activity from human thymocytes. J Immunol. 1987;139:1446. [PubMed] [Google Scholar]
  • 16.Salup RR, Mathieson BJ, Wiltrout RH. Precursor phenotype of lymphokine-activated killer cells in the mouse. J Immunol. 1987;138:3635. [PubMed] [Google Scholar]
  • 17.Shau H, Golub SH. Depletion of NK cells with the lysosomotropic agent L-leucine methyl ester and the in vitro generation of NK activity from NK precursor cells. J Immunol. 1985;134:1136. [PubMed] [Google Scholar]
  • 18.Smith KA. T-cell growth factor. Immunol Rev. 1980;51:337. doi: 10.1111/j.1600-065x.1980.tb00327.x. [DOI] [PubMed] [Google Scholar]
  • 19.Trinchieri G, Matsumoto-Kobayashi M, Clark SC, Seekra J, London L, Perussa B. Response of resting human peripheral blood natural killer cells to interleukin 2. J Exp Med. 1984;160:1147. doi: 10.1084/jem.160.4.1147. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Vose BM, Riccardi C, Bonnard GD, Herberman RB. Limiting dilution analysis of the frequency of human T cells and large granular lymphocytes proliferating in response to interleukin 2. II. Regulatory role of interferon on proliferative and cytotoxic precursors. J Immunol. 1983;130:768. [PubMed] [Google Scholar]
  • 21.Wei-Feng C, Scollay R, Shortman K. The functional capacity of thymus subpopulations: limit-dilution analysis of all precursors of cytotoxic lymphocytes and of all T cells capable of proliferation in subpopulations separated by the use of peanut agglutinin. J Immunol. 1982;129:18. [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES